-Cochlear facing some competition
-Brokers prefer ResMed
-More Sell ratings
-China tender the main positive


By Eva Brocklehurst

Cochlear ((COH)), at the top of the market for hearing implants, is getting some push and shove. A competitor looms, the first serious one in over a decade according to UBS. The company reported flat revenue in the first half, with profit of $77.7 million around 4-5% below broker consensus. Moreover, the road ahead is expected to feature slower established market gains, while the large tender win from China stands out as the main support to earnings growth.

UBS thinks competitor Advanced Bionics' new 40% smaller processor, and